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Abstract
Background—Genome-wide association studies have yet to identify the majority of genetic 
variants involved in asthma. We hypothesized that expression quantitative trait locus (eQTL) 
mapping can identify novel asthma genes by enabling prioritization of putative functional variants 
for association testing.
Objective—We evaluated 6,706 cis-acting expression-associated variants (eSNP) identified 
through a genome-wide eQTL survey of CD4+ lymphocytes for association with asthma.
Methods—eSNP were tested for association with asthma in 359 asthma cases and 846 controls 
from the Childhood Asthma Management Program, with verification using family-based testing. 
Significant associations were tested for replication in 579 parent-child trios with asthma from 
Costa Rica. Further functional validation was performed by Formaldehyde Assisted Isolation of 
Regulatory Elements (FAIRE)-qPCR and Chromatin-Immunoprecipitation (ChIP)-PCR in lung 
derived epithelial cell lines (Beas-2B and A549) and Jurkat cells, a leukemia cell line derived from 
T lymphocytes.
Results—Cis-acting eSNP demonstrated associations with asthma in both cohorts. We confirmed 
the previously-reported association of ORMDL3/GSDMB variants with asthma (combined p=2.9 × 
108). Reproducible associations were also observed for eSNP in three additional genes: FADS2 
(p=0.002), NAGA (p=0.0002), and F13A1 (p=0.0001). We subsequently demonstrated that FADS2 
mRNA is increased in CD4+ lymphocytes in asthmatics, and that the associated eSNPs reside 
within DNA segments with histone modifications that denote open chromatin status and confer 
enhancer activity.
Conclusions—Our results demonstrate the utility of eQTL mapping in the identification of 
novel asthma genes, and provide evidence for the importance of FADS2, NAGA, and F13A1 in the 
pathogenesis of asthma.
Keywords
Asthma; CD4+; lymphocytes; regulatory variants; Expression Quantitative Trait Locus (eQTL); 
Haplotype; Integrative Genomics
Introduction
Genetic factors influence an individual’s asthma susceptibility, with heritability estimates 
ranging from 36–79%1. Among the various genetic mapping techniques used to identify the 
genetic determinants of complex diseases, genome-wide association studies (GWAS) have 
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been most fruitful. Individual studies and two meta-analyses2, 3 have identified common 
sequence variants in at least 10 genes that are consistently associated with asthma in 
children and adults, including the ZPBP2/GSDMB/ORMDL3 locus (17q), IL1RL1 (2q), IL33 
(9p), and TSLP (5q). Though some age- and ethnic-specific trends were noted, these loci are 
widely reproducible and represent important advances in our understanding of asthma. 
However, as with virtually all complex diseases, the identified asthma loci explain only a 
small proportion of the total estimated genetic risk4, suggesting that novel approaches are 
required to identify other genetic variants underlying this “missing heritability.”
Expression quantitative trait loci (eQTL) mapping seeks to identify genetic variants that 
regulate gene expression by considering the distributions of gene transcript abundance for 
thousands of genes (measured using microarrays) as individual quantitative traits5. From 
more than 20 such studies, expression-associated variants (eSNPs) have been mapped for 
thousands of expressed genes, explaining, on average, 5 to 15% of the observed variation in 
gene expression. Though many eSNP demonstrate wide-spread effects across diverse tissue 
types, tissue-specific patterns are often observed. Importantly, we and others have 
demonstrated that, compared to random SNP, identified eSNP are more likely to be 
associated with complex disease traits6, 7. In a study of the HapMap lymphoblastoid cell 
lines (LCLs), Nicolae et al. reported ∼ 2-fold enrichment for eSNP among disease-
associated variants6. Similarly, in primary peripheral blood CD4+ T-cells, we found the 
prevalence of eSNP among disease-associated SNPs was 63% higher than the genome-wide 
average7. These findings suggest that eQTL identification could be leveraged to prioritize 
SNP for association testing and for localization of functional genetic variants.
Given the central role of the CD4+ lymphocyte in allergic responses and the pathogenesis of 
asthma8, 9, we hypothesized that eSNP identified from CD4+ lymphocytes would be 
enriched for asthma–susceptibility variants, thus enabling identification of novel variants 
and their associated candidate genes from existing GWAS data. We tested this hypothesis in 
a study of childhood asthma, the results of which we report here. Some of the results of this 
study have been previously reported in the form of an abstract10.
Methods
We provide a brief description of the cohorts below, with details in the Online Repository. 
The Institutional Review Board of Brigham and Women’s Hospital approved these studies. 
Subject recruitment and procedures for the cohorts have been previously described7, 11, 12
The Childhood Asthma Management Program (CAMP): Discovery Population
The Childhood Asthma Management Program (CAMP) was a multicenter randomized, 
double-blind, placebo controlled clinical trial established to investigate the effects of inhaled 
anti-inflammatory asthma medications11. Children enrolled in CAMP had mild-moderate 
persistent asthma based on the demonstration of airway responsiveness to methacholine 
PC20 (provocative concentration causing a 20% fall in FEV1) less than or equal to 
12.5mg/ml, and at least two of the following: asthma symptoms at least two times per week, 
the use of inhaled bronchodilator at least twice weekly, or the use of daily asthma 
medication for at least six months in the year prior to screening11. DNA was available for 
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403 parent-child trios and an additional 66 singletons of self-reported non-Hispanic white 
ancestry with mild-to moderate persistent asthma, therefore, 469 self-reported white CAMP 
subjects were genotyped with Illumina Infinium II HumanHap 550 or Human610W–Quad 
BeadChips (San Diego, CA). Non-asthmatic controls were selected from 1,533 subjects in 
the Illumina’s iControlIDB resource as previously described13. We generated a genetically 
matched case-control cohort using GEM14, resulting in a final dataset of 359 asthmatic and 
846 control subjects, and 547,497 SNPs.
In 200 CAMP participants, we collected peripheral blood CD4+ lymphocyte RNA and 
performed a genome-wide eQTL analysis for cis-acting eSNP as previously described in 
detail7. Expression profiling was performed using Illumina Human Ref8 v3 array. Similar to 
observations by others, our prior eQTL analysis demonstrated a precipitous fall in the 
prevalence of cis-acting eQTL away from the target gene locus, with a substantial increase 
in the false discovery rates when considering variants more than 50kb from the transcript6, 7. 
Thus, to limit the potential for type I error inflation, we limited our search space to SNPs of 
frequency ≥ 10% situated within 50 kb of the transcript. This analysis resulted in the 
identification of 6,706 cis-acting eSNPs regulating 1,585 genes7. Given our prior studies 
demonstrating enrichment of susceptibilty variants for eSNP, in this current study we 
prioritized these 6,706 variants for asthma-association testing in the CAMP cohort. An 
overview of our study design in shown in Supplemental Figure E1.
CAMP: Asthma-susceptibility eSNP association testing
Case-control asthma association analysis was performed for the 6,706 eSNP detected in 
CD4+ lymphocytes using PLINK15, with EIGENSTRAT adjustment16, and retested in a 
subset of 403 available parent-child trios using PBAT. Haplotype association testing was 
conducted using Haploview (for asthma) and haplo.score (for expression traits).
Replication of Genetic Associations in the Genetic Epidemiology of Asthma in Costa Rica 
Cohort (GACRS)
Replication studies were performed in 579 parent-child trios recruited as part of the Genetic 
Epidemiology of Asthma in Costa Rica cohort. Details on subject recruitment and study 
protocols have been published elsewhere12. In brief, children ages 6 to 14 years were 
included in the study if they had asthma (a physician’s diagnosis of asthma and ≥ 2 
respiratory symptoms or asthma attacks in the previous year) and a high probability of 
having ≥ 6 great-grandparents born in the Central Valley of Costa Rica, which increased the 
likelihood that children would be descendants of the founder population of the Central 
Valley12.
Only the variants that demonstrated a nominal association with asthma in CAMP (p<0.01) 
were tested for association with asthma susceptibility in the Costa Rican cohort using 
family-based methods in PBAT. The transmitted to untransmitted ratio (T:U ratio) for the 
significant associations were identified in PLINK. Results were considered significant when 
identical associations (i.e. same allele, phenotype, and direction of genetic effect) were 
identified in both populations. Fisher’s combined p-value method was applied to assess the 
cumulative significance of association across populations17.
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Validation: Expression of novel asthma genes between asthmatics and non-asthmatic 
controls in Asthma BRIDGE
Expression of the FADS2, NAGA, and F13A1 genes was compared between asthmatic 
subjects (n=300) and non-asthmatic controls (n=122) based on gene expression profiling in 
CD4+ lymphocytes from the Asthma BioRepository for Integrative Genomic Exploration 
(Asthma BRIDGE). Asthma BRIDGE is a multicenter-collaborative effort to develop well-
characterized translational genomic datasets for asthma in North America18. Samples were 
collected through October 2011 from among more than 14,000 subjects studied by the EVE 
Consortium, providing broad representation of the North American asthmatic population. 
Genome-wide gene-expression data (Illumina Human HT-12 v4 array) was generated from 
asthma-relevant primary cell types, including peripheral blood CD4+ lymphocytes. 
Differential expression of FADS2, NAGA, and F13A1 was determined using a linear model 
adjusted for age, gender, and race using the limma package in Bioconductor19.
Functional Validation: Chromatin enrichment studies
Human Beas-2B (#CRL-9609, ATCC) and A549 (#CCL-185, ATCC) cells were cultured in 
complete DMEM medium, and Jurkat (TIB-152, ATCC) cells were cultured in RPMI 1640 
medium, all supplemented with 10% FBS, penicillin (50 units/ml), streptomycin (50 mg/ml) 
and gentamicin (10 µg/ml). Additional details can be found in the online repository.
For FAIRE (Formaldehyde-Assisted Isolation of Regulatory Elements) and Chromatin 
immunoprecipitation (ChIP) followed by real-time PCR, see details in Online Repository. 
The sequence of primers used in FAIRE-qPCR and ChIP-qPCR was listed in Supplemental 
Table E1.
Results
Asthma association testing of eSNP
The baseline characteristics of the CAMP and Costa Rican index cases included in this study 
are presented in Table 1. Baseline characteristics were similar between the CAMP and Costa 
Rican cohorts including measures of asthma severity and lung function.
Of the 6,706 SNP identified as CD4+ lymphocytes cis-acting expression associated eSNP, 
143 were associated with asthma under an additive genetic model in the CAMP cohort in 
either the case-control or family-based association analyses (Supplemental Table E2). To 
confirm their associations, we next genotyped these 143 variants in the Costa Rican cohort. 
Associations were reproduced in this independent, ethnically distinct cohort for multiple 
variants in four genes (Table 2). Firstly, we were able to replicate the association of the 
chromosome 17q ORMDL3/GSDML locus with asthma20. Specifically, two variants 
(rs4795405 and rs7216389) were strongly associated with asthma in both cohorts (Fisher’s 
combined p value= 2.9 × 10−8 and 3.4 × 10−7, respectively). The T allele of rs4795405 allele 
was associated with decreased ORMDL3 expression (Figure 1A)7, and confers a decreased 
risk of asthma in two independent cohorts. As previously reported, these variants reside on a 
haplotype that includes rs1293623, a functional regulatory polymorphism that alters DNA 
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binding affinity with the insulator CTCF, resulting in differential expression of three 
surrounding genes: ORMDL3, GSDML and ZPBP221.
We also found consistent association in both cohorts for three loci never previously 
associated with asthma susceptibility: the Fatty Acid Desaturase locus (FADS1/FADS2) on 
11q, N-acetyl galactosaminidase (NAGA) on chromosome 22q, and the factor XIII A subunit 
(F13A1) locus on chromosome 6p. On chromosome 11q12.2, the minor C allele of rs174611 
(C) is associated with increased expression of two adjacent members of the fatty-acid 
desaturase gene cluster (FADS1 and FADS2, FDR p=0.001 and 0.0007, respectively, Figure 
1B). The C allele of this variant confers an increased risk of asthma in both CAMP and 
Costa Rica (Fisher’s combined p value=0.002). On chromosome 22q13.2, the C allele of 
SNP rs2413669, located ∼40kb upstream of the transcription start site of the alpha-N-
acetylgalactosaminidase precursor gene (NAGA), was associated with decreased NAGA 
expression (FDR p=0.0003, Figure 1C), as well as with decreased odds of asthma in both 
cohorts (Fisher’s combined p=0.0002). On chromosome 6p25.1, the T allele of variant 
rs11243081 was associated with increased expression of the coagulation factor XIII A1 gene 
(F13A1, FDR p=0.0009, Figure 1D), as well as with increased asthma susceptibility in both 
cohorts (Fisher’s combined p=0.0001). Of note, the magnitudes of the effect for each of 
these genetic variants on asthma susceptibility were similar in both cohorts.
Haplotype testing of asthma-associated regulatory loci
Using genome-wide genotypic data available in CAMP subjects, we next tested haplotype 
blocks for each of the three novel genes identified in this study for association with gene 
expression and asthma susceptibility. Figure 2 illustrates the results of the association 
analyses of the FADS 2 locus. SNP rs968567, located in a conserved promoter region of the 
FADS2 locus, was associated with FADS2 expression (p=10−15), explaining 30% of its 
variance. In addition, the minor allele of SNP rs174611, which is associated with asthma in 
CAMP and Costa Rica, explains 11% of the variance in FADS2 gene expression (p=0.0007) 
and 5.3% of the expression in FADS1 (p=0.03). Figure 3a shows the haplotype structure of 
the FADS2 locus. The T allele of SNP rs968567 uniquely tags a common haplotype in block 
2 (H2), which is observed in 18.1% of the subjects. SNPs rs174627 and rs174611 are in 
linkage disequilibrium (LD) with SNP rs968567; all three of these variants and the FADS 
H2 haplotype are associated with asthma susceptibility in the CAMP cohort (p= 0.001 to 3 
×10−4). Furthermore, as seen in Figure 3b, haplotype 2 is associated with increased FADS2 
expression (p=10−10), suggesting that this is a functional regulatory haplotype in the FADS 
region.
In contrast, the genomic region of eQTL association for F13A1 is relatively narrow 
(Supplemental Figure E2) despite of its relative large gene size: 177kb. Although there are 
three haplotype blocks demonstrating eQTL association (Supplemental Table E4), only one 
block (Block 9) is strongly associated with both F13A expression (p=0.0007) and also with 
asthma (p = 0.003).
In the NAGA association analysis, the minor allele of SNP rs2413669 explains 6% of the 
variation in expression of NAGA (Supplemental Figure E3, p=0.0003). However, unlike the 
FADS and F13A1 loci, haplotype block analysis did not help localize the functional variant: 
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haplotype blocks in NAGA were not significantly associated with either asthma or NAGA 
expression (p≥0.05), suggesting the functional regulatory variant likely resides on more than 
one haplotype, in LD with the asthma-associated eSNP rs2413669.
Validation: Differential FADS2 expression in asthma in Asthma BRIDGE
Having demonstrated that variants that regulate gene expression in CD4+ lymphocytes were 
reproducibly associated with asthma, we next assessed whether the expression of target 
genes were similarly correlated with asthma status. We therefore assessed the expression of 
FADS2, NAGA and F13A1 in 300 asthma cases and 122 non-asthmatic controls participating 
in Asthma BRIDGE with available expression data in peripheral blood CD4+ lymphocytes 
(see Supplemental Table E3 for baseline characteristics of the cohort used for this analysis). 
Of the three genes evaluated, FADS2 mRNA expression was significantly increased in 
asthmatics compared to non-asthmatic controls (p=0.003, Figure 4). FADS1 expression was 
also modestly increased in asthma cases compared to controls (p=0.04), and a trend towards 
increased NAGA expression was also observed in asthma cases (p=0.05). There was no 
evidence of asthma-related differential expression of F13A1 (p=0.60).
Functional Validation: Open chromatin enrichment studies
The expression-associated regulatory variants identified by eQTL mapping are often 
surrogates for functional regulatory variation situated in neighboring regulatory DNA 
regions22, 23. However, given that the FADS2 rs968567 regulatory variant uniquely tags the 
asthma-associated H2 haplotype, and the NAGA rs2413669 variant (but not NAGA 
haplotypes) is associated with asthma and NAGA expression, it is possible that these two 
disease associated eSNPs are not merely surrogates or tagging variants, but actually 
represent the functional variants regulating the target gene expression thus driving the 
asthma association. To assess this, we first screened for active regulatory activity at the three 
loci by FAIRE-qPCR, a method used to detect open chromatin regions devoid of 
nucleosomes24. Given that the eQTL analysis was performed in CD4+ T cells, we chose the 
Jurkat acute T cell leukemia cell line, in addition to two respiratory epithelial cell lines: 
Beas-2B (human bronchial epithelial cells) and A549 (human alveolar type II-like 
pneumocyte). Three SNPs that showed association with asthma in each region were chosen 
for open chromatin assessments in these cell lines. As shown in Figure 5, the FADS2 
associated SNP rs968567 showed ∼15 fold enrichment of FAIRE signals in A549 and 
Jurkat cells and ∼ 5 fold enrichment in Beas-2B cells compared to the negative control 
region (p<0.01, unpaired t test), consistent with previous finding that rs968567 is a 
functional SNP with differential binding to transcription factor ELK-125. Furthermore, in the 
NAGA association region, we observed strong enrichment of FAIRE signals near rs1801311 
in Jurkat cells as well as in Beas-2B and A549 cells. In contrast, FAIRE signals in SNPs 
around the F13A1 region were relatively weak, suggesting these SNPs are not themselves 
functional, but rather tag the causal variants within block 9.
Epigenetic modifications on histone tails of nucleosomes usually indicate active or 
repressive transcriptional regulations26. To further confirm our finding about potential 
regulatory SNPs indicated by FAIRE, we applied ChIP-PCR with antibodies targeting two 
enhancer markers H3K4Me1 (indicating enhancer regions) and H3K27Ac (indicating active 
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enhancer and/or promoter regions) in the FADS2 and NAGA regions in Beas-2B, A549 and 
Jurkat cells (Figure 6). Consistent with FAIRE enrichment signals, H3K27Ac showed 
significant enrichment at two SNPs we tested in FADS2 and NAGA regions in almost all 
three cell lines, indicating active regulatory elements are contained in both the NAGA and 
FADS2 regions near eSNPs.
Discussion
Although GWAS of complex traits have offered insights into the genetic underpinnings of 
complex diseases like asthma, the discovered variants explain only a fraction of the genetic 
contribution to such diseases4. In some part, this is likely due to the stringent multiple 
comparisons burden imposed when testing millions of (mostly functionless) variants. 
Strategies that guide prioritization of functional genetic markers for testing can address this 
issue. We and others have demonstrated that eSNP are more likely to be disease-associated 
variants6, 7 suggesting eQTL mapping as a promising strategy. Using asthma as a model, we 
sought to evaluate this possibility by testing cis-acting regulatory variants previously 
identified from an eQTL mapping study of peripheral blood CD4+ lymphocytes for 
association with asthma in two well-characterized populations. Using this integrative 
genomic approach in CAMP subjects, we have not only replicated the association of the 17q 
ORMDL3/GSDMB locus for association with asthma in two childhood asthma cohorts, but 
have also defined three novel candidate loci. These later associations did not emerge from 
prior studies as their nominal association p-values were below the threshold for multiple 
comparisons correction. Though our application of a functional prioritization strategy using 
eQTL data led to consideration and successful independent replication of these loci in the 
Costa Rican cohort, supporting application of such strategies for identification of novel 
disease candidate genes, they will require follow-up replication testing to assess whether the 
results are generalizable. We also recognize that the relatively small size of our test and 
replication cohorts may have precluded identification of additional asthma variants due to 
limits in statistical power. Application of eQTL approaches to larger populations is 
warranted. In addition, consideration should be extended beyond cis-acting regulatory 
variants once adequately powered studies identify validated, reproducible trans-acting 
eQTLs.
Of three novel genes identified in this study, the greatest biological and epidemiological 
support is provided for FADS2 and the fatty acid desaturase gene cluster on chromosome 11. 
The FADS1 and FADS2 genes respectively encode for Δ5- and Δ6-desaturase - enzymes that 
are critical for long chain poly-unsaturated fatty acid (PUFA) biosynthesis, which are the 
precursors of eicosanoid mediators that are critical to the development and resolution of 
allergic inflammation27, 28. PUFAs are synthesized from two essential fatty acids: linoleic 
acid (LA;18:2n-6) and alpha-linolenic acid (ALA; 18:3n-3). Desaturase enzymes introduce 
double bonds between defined carbons of the fatty acyl chain. Δ6-desaturase (FADS2) 
catalyzes the first rate-limiting step in long chain PUFA biosynthesis by causing 
desaturation of LA and ALA. In our study, we demonstrate association of eSNPs in FADS2 
with asthma in two cohorts, and localize the most robust associations to a haplotype-tagging 
variant - rs968567, situated in the promoter of FADS2 that is strongly associated with 
FADS2 (and to a lesser degree FADS1) expression. We also detected increased expression of 
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FADS2 in peripheral blood CD4+ lymphocytes of asthmatics in a large population sample, 
consistent with increased expression of FADS2 conferred by asthma risk allele in this locus. 
In addition, rs968567 demonstrates strong enrichment for open chromatin status in both 
lymphocyte and bronchial epithelial cell lines. In hepatocytes, this same variant exhibits 
differential binding of the ELK1 transcription factor25. This variant, and others in strong LD 
with it, have been strongly associated with circulating PUFA29, total cholesterol and high-
density lipoprotein, and omega-3 fatty acid levels30. Perhaps most pertinent in the context of 
asthma pathogenesis, a recent GWAS study in a general population sample29 found this 
FADS2 promoter variant to explain 19% of the population variance in serum levels of 
arachadonic acid (AA) – the precursor for pro- and anti-inflammatory prostaglandins and 
leukotrienes27.
Due to their roles in the production of pro-inflammatory and anti-inflammatory eicosanoids, 
and evidence for PUFAs in the alteration of T-cell antigen presentation31, others have 
investigated the role of FADS1/FADS2 polymorphism in atopic disease, with variable 
results. In one candidate-gene birth cohort study of 879 children, FADS variants that were 
associated with PUFA and AA serums levels were also associated with increased eczema 
risk32. In contrast, these same variants were inversely associated with eczema and allergic 
rhinitis in an adult population33. In addition, recent work by Standl and colleagues 
demonstrated that genetic variants in the FADS cluster modify the effect of breastfeeding on 
the development of asthma with the lowest risk noted in children who were exclusively 
breast fed for the first three months of life34. Although the biologic mechanism underlying 
this association is unclear, the authors speculate that carriers of the minor allele have lower 
fatty acid metabolism and, thus, less arachadonic acid levels34. Though replication of these 
interactions have yet to be reported, if true, such interaction could represent an important 
modifier of our observed associations between FADS2 genotype and asthma susceptibility, 
posing greater challenges to replication in additional populations. Although none of these 
studies focused exclusively on asthma, making direct comparisons with our initial 
observations difficult, assuming a direct correlation between asthma and risk for other atopic 
diseases, our findings are consistent with those in the pediatric cohort, with high FADS2 
expression associated with increased asthma and atopic risk. The associations may be age 
dependent (explaining the different findings in adults), or modified by dietary PUFA intake. 
While these possibilities must be tested in other populations, the evidence presented here, 
together with that from prior studies support FADS2 as a biologically plausible asthma-
susceptibility gene.
In contrast to FADS2, the roles of NAGA and F13A1 in asthma pathogenesis are less clear. 
NAGA is a lysosomal glycohydrolase that cleaves the alpha-N-acetylgalactosaminyl moieties 
from glycol-conjugates. NAGA has been implicated as part of the carbohydrate-mediated 
mechanism of mast cell adhesion to the bronchial epithelium35. Treatment of mast cells of 
endo-α-N-acytelgalactosaminidase, an enzyme that cleaves disaccharides on the cell surface 
of the mast cell, results in a significant reduction of mast cell adhesion to bronchial 
epithelium and changes in airway responsiveness35. Moreover, a guinea pig model 
demonstrated increased NAGA released from bronchoalveolar macrophages in animals with 
increased airways responsiveness following high ozone exposure36. Though speculative, 
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given the central role of macrophages and mast cell degranulation in bronchoconstriction, 
mucus secretion, and airway inflammation in asthmatics37, the asthma-associated NAGA 
eSNP may influence asthma risk through altered glycohydrolase activity.
F13A1 encodes the alpha subunit of factor X111, the last enzyme generated in the blood 
coagulation cascade, stabilizing blood clots by cross-linking fibrin. F13A1 has also been 
implicated in the inflammatory cascade and in atopy38. When stimulated with dust-mite 
antigen, peripheral blood mononuclear cells from dust-mite allergic patients demonstrate 
increased production of F13A139. F13A1 has also been implicated as a susceptibility locus 
for obesity40. Epidemiologic data demonstrates a consistent link between asthma and 
obesity41, with apparent shared genetic determinants42. How F13A1 regulatory variation 
confers susceptibility to asthma, and whether F13A1 represents a shared genetic determinant 
of both asthma and obesity, remains unclear. In addition to replication in additional asthma 
populations, further characterization of the functional impact of these variants in model 
systems will be needed to resolve these questions.
Though we have demonstrated the utility of eQTL mapping for the identification of asthma-
susceptibility variants, our studies were limited in scope, particularly in regards to the 
narrow focus on cis-acting regulatory variation in only one cell type − the CD4+ 
lymphocyte. Although this cell type is relevant to allergic cytokine profiles and asthma, it is 
only one of many cell types of potential interest. Given that a substantial proportion of cis-
acting regulatory variants demonstrate tissue-specific effects, we have likely overlooked 
some functional variation specific to other relevant cell types, including antigen presenting 
cells, granulocytes, airway smooth muscle and bronchial epithelium. A recent eQTL study in 
human lung tissue samples provides complementary evidence at the 17q locus, suggesting a 
potential role for altered expression of GSDMA, in addition to the altered ORMDL3 and 
GSDMB expression noted by us and others in lymphocytic lines43. Thus, we view these 
initial efforts as the first step of a more integrative approach to disease gene mapping that 
considers eQTL variation across multiple tissue types, in diverse patient populations, and 
under disease-relevant environmental exposures and that also considers other functional 
annotations, including chromatin modification, CpG methylation differences, and other 
epigenetic modifications44. Such comprehensive, more holistic approaches, combined with 
powerful systems based analytical tools, should provide a more complete picture of the 
genetic landscape in asthma.
In summary, we provide new evidence in support of FADS2, NAGA, and F13A1 as asthma-
susceptibility loci. Similar to variants previously identified through GWAS and other 
genetic approaches, the relatively modest effect sizes conferred by these loci limit their 
clinical utility as diagnostic or prognostic markers. Instead, our observations motivate 
prioritization of these loci and their related pathways for further investigation. Of these, we 
find strongest support for a common promoter polymorphism in the FADS2 gene, which 
regulates FADS2 expression, is associated with asthma and allergic phenotypes, and has 
been previously shown to be the major genetic determinant of plasma arachadonic acid 
levels – the major precursor of asthma-relevant eicosanoids. Though replication of these 
associations in additional populations is warranted, these findings should prompt revisiting 
this important pathway as a potential therapeutic asthma target.
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Key Messages
• Integrative genomic approaches including expression quantitative trait loci 
(eQTL) mapping can be used to prioritize genetic variants for disease 
susceptibility testing.
• Using a genome-wide survey of regulatory genetic variants in peripheral blood 
CD4+ lymphocytes sampled from subjects with asthma, we identified novel 
asthma susceptibility loci, including FADS1/FADS2, NAGA, and F13A1.
• Functional variants can be further localized through a combination of eQTL 
mapping with assessments of chromatin status and modifications nearby eQTL 
SNPs.
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Figure 1. 
Genome-wide significant expression quantitative trait loci (eQTLs) previously identified in 
CD4 positive lymphocytes of asthmatic subjects. A. Association of SNP rs4795405 with the 
expression of ORMDL3. B. Association of SNP rs174611 with FADS2 expression. C. 
Association of SNP rs2413669 with NAGA expression. D. Association of rs11243081 with 
F13A1 expression.
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Figure 2. SNP-based eQTL analysis across the FADS2 locus
SNP-based eQTL analysis across FADS2, demonstrating association of rs968567 with 
FADS2 expression (p=10−15, 30% expression variance explained). SNP rs968567 (blue 
arrow), located in a conserved region of the promoter, demonstrates association with FADS2 
expression (p=10−15). SNPs rs174627 (green arrow) and rs174611 (red arrow) are in LD 
with rs968567 and are associated with FADS2 expression and asthma susceptibility.
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Figure 3. Haplotype analysis of the FADS2 locus
(a) Haplotype structure: Haplotype frequencies observed in at least 1% of CAMP subjects 
are listed to the right of each haplotype sequence. Dots indicate the allele present in 
haplotype H1 – the most common haplotype. The asthma-associated rs968567 T allele is 
unique to, and uniquely tags, haplotype 2 (H2, boxed in blue), observed at 18.1% frequency. 
(b) Haplotype-based eQTL analysis: H2 demonstrates strong association with increased 
FADS2 expression (p<10−10), while haplotype 1 (H1, frequency 31.4%) is associated with 
low FADS2 expression. Others (H3-H8) showed intermediate levels of FADS2 expression.
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Figure 4. Differential expression of FADS2 in asthmatic subjects compared to non-asthmatic 
controls in Asthma BRIDGE
Significantly increased expression of FADS2 in peripheral blood CD4+ lymphocytes of 
asthmatic subjects compared to non-asthmatic control subjects (p=0.003)
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Figure 5. Functional annotation of the three asthma associated regions by FAIRE-PCR analysis
Formaldehyde assisted isolation of regulatory enrichment (FAIRE) was performed at three 
association regions nearby FADS2, NAGA and F13A genes in Beas-2B, A549 and Jurkat cell 
lines by real-time PCR analysis. The graph depicts the relative FAIRE signal at each locus 
normalized to input and negative control regions. Each locus contains three SNPs nearby 
eQTL signals. Mean±SD are from two to four repeats for each SNP. **p<0.01 (unpaired one 
way t test.)
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Figure 6. Enrichment of active histone marks in two asthma associated regions detected by 
ChIP-PCR analysis
Chromatin immunoprecipitation (ChIP) was performed using H3K4Me1 and H3K27Ac 
antibodies in Beas-2B, A549 and Jurkat cell lines targeting genomic regions nearby two 
SNPs rs968567 and rs1801311 in FADS2 and NAGA loci respectively. IgG was used as a 
negative control. The bars represent the average of a two biological replicates with standard 
deviations. * p<0.05; ** p<0.01 (paired one way t test).
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Table 1
Baseline phenotypic characteristics of index children in CAMP and Costa Rica
Variable
CAMP
n=359
Costa Rica
n=579
Age (years) 8.8 (2.1) 9.1 (1.8)*
Female sex 137 (38%) 222 (41%)
Height (cm) 132.7 (13.3) 131.0 (11.2)
Baseline pre-bronchodilator FEV1
(L)
1.6 (0.5) 1.7 (0.5)
Baseline pre-bronchodilator
FEV1/ FVC (%)
79.1 (8.3) 82.6 (7.2)
*
Mean (standard deviation) or count (frequency) reported
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